Main clinical characteristics and outcomes of cHL patients (N = 89)
| Characteristic . | No. (%) . |
|---|---|
| Median age, y (range) | 29 (13-89) |
| 45 or older | 15 (17) |
| Sex, male/female | 42/47 (47/53) |
| Histology | |
| Nodular sclerosis | 70 (79) |
| Mixed cellularity | 19 (21) |
| EBV+ | 25 (28) |
| HIV+ | 7 (8) |
| B symptoms | 36 (40) |
| Bulky mass | 21 (24) |
| Anemia (Hb < 105 g/L) | 16 (18) |
| Leukocytosis, > 15 × 109/L | 12 (13) |
| Lymphocytopenia, < 0.6 × 109/L or < 8% of WBCs | 10 (11) |
| Hypoalbuminemia, < 40 g/L | 24 (29) |
| High LDH, > 450 UI/L | 29 (33) |
| High β2-microblobulin, > 2.5 mg/dL | 15 (17) |
| Stage | |
| I-II | 54 (61) |
| III-IV | 35 (39) |
| Hasenclever index ≥ 3* | 16 (27) |
| Characteristic . | No. (%) . |
|---|---|
| Median age, y (range) | 29 (13-89) |
| 45 or older | 15 (17) |
| Sex, male/female | 42/47 (47/53) |
| Histology | |
| Nodular sclerosis | 70 (79) |
| Mixed cellularity | 19 (21) |
| EBV+ | 25 (28) |
| HIV+ | 7 (8) |
| B symptoms | 36 (40) |
| Bulky mass | 21 (24) |
| Anemia (Hb < 105 g/L) | 16 (18) |
| Leukocytosis, > 15 × 109/L | 12 (13) |
| Lymphocytopenia, < 0.6 × 109/L or < 8% of WBCs | 10 (11) |
| Hypoalbuminemia, < 40 g/L | 24 (29) |
| High LDH, > 450 UI/L | 29 (33) |
| High β2-microblobulin, > 2.5 mg/dL | 15 (17) |
| Stage | |
| I-II | 54 (61) |
| III-IV | 35 (39) |
| Hasenclever index ≥ 3* | 16 (27) |
Calculated only in 59 patients with advanced disease (stages III-IV, B symptoms, or bulky mass).